<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25150" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Migraine Prophylaxis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kumar</surname>
            <given-names>Anil</given-names>
          </name>
          <aff>Great Plains Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kadian</surname>
            <given-names>Renu</given-names>
          </name>
          <aff>Great Plains Health</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anil Kumar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Renu Kadian declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25150.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Recurrent migraines can be functionally disabling and can impair quality of life. After treating acute migraines, all migraine patients should be evaluated for preventive therapy. Preventive therapy aims to decrease the frequency, severity, and duration of migraine attacks. Furthermore, preventative therapy can increase responsiveness to acute migraine therapy and improve the quality of life. Prophylactic treatment is not curative, and most patients will still need abortive medications for acute migraine. Before starting prophylactic medications, it is imperative to evaluate if patients are using proper and adequate abortive therapies. Overuse of abortive medications can cause rebound headaches. This activity reviews the evaluation and treatment of migraine prophylaxis and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the frequency of migraine headaches.</p></list-item><list-item><p>Describe the appropriate history that should be taken in the evaluation of migraine headaches.</p></list-item><list-item><p>Outline the prophylactic treatment options for migraine headaches.</p></list-item><list-item><p>Summarize simple education strategies the interprofessional team can use to help to identify patients needing prophylactic migraine treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25150&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25150">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25150.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Recurrent migraines can be functionally disabling and can impair quality of life. The disabling nature of migraine headaches leads to frequent visits to outpatient clinics and emergency department facilities, causing significant health and financial burdens. Headaches fall in the top five causes of emergency department visits and the top twenty reasons for outpatient visits.<xref ref-type="bibr" rid="article-25150.r1">[1]</xref>&#x000a0;The overall prevalence of migraine headaches is estimated to be 16%; they are more frequent in women, with a sex prevalence ratio of 3:1.<xref ref-type="bibr" rid="article-25150.r1">[1]</xref>&#x000a0;Around 38% of patients with episodic migraines would benefit from prophylactic treatment, but only 3% to 13% get it.<xref ref-type="bibr" rid="article-25150.r2">[2]</xref></p>
        <p>After treating acute migraines, all migraine patients should be evaluated for preventive therapy. The purpose of preventive therapy is to decrease the frequency, severity, and duration of migraine attacks. Furthermore, preventative therapy can increase responsiveness to acute migraine therapy&#x000a0;and improve the quality of life.</p>
        <p>Prophylactic treatment is not curative, and most patients will still need abortive medications for acute migraine. Before starting prophylactic medications, it is imperative to evaluate if patients are using proper and adequate abortive therapies. Overuse of abortive medications can cause rebound headaches.<xref ref-type="bibr" rid="article-25150.r2">[2]</xref><xref ref-type="bibr" rid="article-25150.r3">[3]</xref></p>
      </sec>
      <sec id="article-25150.s3" sec-type="Function">
        <title>Function</title>
        <p>Approximately 28 million Americans older than 12 suffer from migraine headaches. Around 18% of women and 6% of men in the United States suffer&#x000a0;from migraine headaches. About 38% of those with a migraine headache need to be on preventive therapy, whereas only 3% to 13% of migraine sufferers use preventative treatment.<xref ref-type="bibr" rid="article-25150.r2">[2]</xref><xref ref-type="bibr" rid="article-25150.r3">[3]</xref></p>
        <p>Prophylactic migraine treatment should be considered in patients with more than three monthly episodes or at least eight headache days in one month.<xref ref-type="bibr" rid="article-25150.r4">[4]</xref><xref ref-type="bibr" rid="article-25150.r5">[5]</xref> Patients with severe debilitating headaches despite appropriate acute treatment or those who are intolerant or have contraindications to acute therapy. Prophylaxis should also be considered in patients with medication overuse headaches, certain migraine subtypes like hemiplegic migraine, basilar migraine, migraine with prolonged aura, or if the patient prefers.<xref ref-type="bibr" rid="article-25150.r2">[2]</xref><xref ref-type="bibr" rid="article-25150.r3">[3]</xref><xref ref-type="bibr" rid="article-25150.r4">[4]</xref></p>
        <p>
<bold>Prophylactic Treatment for Migraine Headache</bold>
</p>
        <p>It is important to determine the frequency, duration, and severity of headaches and any triggers that may precipitate them. All patients with migraine headaches&#x000a0;should&#x000a0;maintain a headache diary to determine the frequency, severity, and duration of headaches. It also helps identify any triggers that can cause a migraine headache. Some common triggers include environmental factors such as noise, odor, medications (like oral contraceptive pills, hormone replacement therapy, and H2-receptor blockers), food (cheese, wine, chocolate), and behavioral factors such as sleep deficit or excessive sleep.<xref ref-type="bibr" rid="article-25150.r6">[6]</xref>&#x000a0;Preventive drug therapy may not be needed if triggers can be identified and modified.<xref ref-type="bibr" rid="article-25150.r7">[7]</xref></p>
        <p>
<bold>1. Pharmacological Therapies for Migraine Prevention</bold>
</p>
        <p>Various medications are available for migraine prophylaxis and prevention. Choosing the right agent is essential. The efficacy, side effects, contraindications, cost, and compliance should be considered when deciding on the right agent. It is also crucial to consider&#x000a0;comorbid medical conditions and drug interactions. Efficacy of treatment can be assessed only after a 2 to 3-month trial; a full trial may take up to 6 months. Always start at&#x000a0;a low dose and titrate up slowly. Monotherapy is preferred as there are no significant benefits of using more than one drug unless indicated for other comorbid conditions. Patients should be re-evaluated, and medications preferably discontinued after one year, even if they show improvement in symptoms. Successful therapy is defined as a reduction of migraine attacks by at least 50%.<xref ref-type="bibr" rid="article-25150.r3">[3]</xref><xref ref-type="bibr" rid="article-25150.r4">[4]</xref><xref ref-type="bibr" rid="article-25150.r8">[8]</xref></p>
        <p>Migraine attacks are associated with neuronal activation, which is thought to be due to cortical spreading activation (CSD)&#x000a0;or a brainstem generator. Preventive medications inhibit CSD through various mechanisms, such as blocking calcium and sodium channels, blocking gap junctions, and inhibiting matrix metalloproteinases.<xref ref-type="bibr" rid="article-25150.r9">[9]</xref><xref ref-type="bibr" rid="article-25150.r10">[10]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Beta-blockers</bold>
</p>
          </list-item>
        </list>
        <p>Propranolol is the most common and one of the most effective first-line medications used for migraine prophylaxis.<xref ref-type="bibr" rid="article-25150.r11">[11]</xref> The starting dose is 40 mg and can go up to 320 mg daily. It may take up to 12 weeks at an adequate dose for therapeutic benefits to become apparent.</p>
        <p>Other beta-blockers that can be used are timolol, atenolol, and metoprolol.<xref ref-type="bibr" rid="article-25150.r12">[12]</xref> They should be considered in patients with underlying cardiovascular disease. Common side effects of this group of medications are fatigue, nausea, dizziness, decreased exercise tolerance, and depression. Contraindications include severe asthma, peripheral vascular disease, severe bradycardia, and heart blocks.<xref ref-type="bibr" rid="article-25150.r3">[3]</xref><xref ref-type="bibr" rid="article-25150.r13">[13]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Anticonvulsants</bold>
</p>
          </list-item>
        </list>
        <p>Depakote and sodium valproate are&#x000a0;two anticonvulsant drugs used for migraine prophylaxis.<xref ref-type="bibr" rid="article-25150.r14">[14]</xref> They are among the first-line&#x000a0;agents used for migraine prevention. They are particularly&#x000a0;useful for prolonged and atypical migraines. Common side effects include nausea, drowsiness, hair loss, tremors, and hyperammonemia. They are contraindicated in patients with severe liver disease and pancreatitis. Sodium valproate cannot be used in pregnancy because of teratogenicity.</p>
        <p>Topamax is another drug used as a first-line treatment option for migraine prophylaxis.<xref ref-type="bibr" rid="article-25150.r15">[15]</xref> Topamax has comparable efficacy to propranolol for preventing migraine headaches. It should be started at a low dose of 25 mg daily and slowly titrated up to 100 mg twice daily. Patients should continue treatment for at least 2 to 3 months before the treatment&#x000a0;efficacy is evaluated. Common side effects include memory and concentration problems, paresthesia, fatigue, nausea, and anorexia. Topamax can cause metabolic acidosis and precipitate kidney stones, acute myopia, and angle-closure glaucoma.</p>
        <p>Gabapentin has little efficacy for migraine prevention. The recommended dose is from 1200 to 2400 mg per day. Common side effects include somnolence and dizziness.<xref ref-type="bibr" rid="article-25150.r16">[16]</xref><xref ref-type="bibr" rid="article-25150.r17">[17]</xref><xref ref-type="bibr" rid="article-25150.r18">[18]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Antidepressants</bold>
</p>
          </list-item>
        </list>
        <p>Amitriptyline is shown to&#x000a0;be beneficial&#x000a0;in migraine prevention.<xref ref-type="bibr" rid="article-25150.r19">[19]</xref> It may be more effective than propranolol in mixed migraine-tension types of headaches. Response to treatment can be seen in up to 4 weeks and is more rapid than with beta-blockers. The&#x000a0;daily dosing is 25 to 150 mg daily.</p>
        <p>Another antidepressant that is probably effective in migraine prevention is venlafaxine.<xref ref-type="bibr" rid="article-25150.r20">[20]</xref> It is probably as effective as amitriptyline. The dose used is 150 mg daily. Fluoxetine has also been used for migraine prophylaxis. Common side effects include weight gain, drowsiness, dry mouth, and urinary retention. Contraindicated in concurrent use with monoamine oxidase inhibitors (MAOIs).<xref ref-type="bibr" rid="article-25150.r3">[3]</xref><xref ref-type="bibr" rid="article-25150.r13">[13]</xref><xref ref-type="bibr" rid="article-25150.r19">[19]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Calcium-channel Blockers</bold>
</p>
          </list-item>
        </list>
        <p>The efficacy of calcium channel blockers in the preventive treatment of migraine is weak. Verapamil has shown weak efficacy in preventing migraines. It is used as one of the second-line pharmacological options for migraine prophylaxis.</p>
        <p>Flunarizine is a nonspecific&#x000a0;calcium channel blocker that has shown evidence of some efficacy. It is not available in the United States.<xref ref-type="bibr" rid="article-25150.r3">[3]</xref><xref ref-type="bibr" rid="article-25150.r13">[13]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Angiotensin Blockers: ACE-Is/ARBs</bold>
</p>
          </list-item>
        </list>
        <p>Lisinopril and candesartan have shown some weak efficacy for migraine prevention.<xref ref-type="bibr" rid="article-25150.r21">[21]</xref><xref ref-type="bibr" rid="article-25150.r22">[22]</xref><xref ref-type="bibr" rid="article-25150.r13">[13]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Non-steroidal Anti-inflammatory&#x000a0;Drugs (NSAIDs)</bold>
</p>
          </list-item>
        </list>
        <p>They are used for the prevention of menstrual migraine. Start treatment a few days before the anticipated start of the menstrual cycle and continue for the first few days.<xref ref-type="bibr" rid="article-25150.r23">[23]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Triptans</bold>
</p>
          </list-item>
        </list>
        <p>Zolmitriptan, frovatriptan, and naratriptan have shown benefits in the short-term prevention of menstrual-related migraines. They are started several days before the expected onset and continued for 5 to 6 days.<xref ref-type="bibr" rid="article-25150.r24">[24]</xref><xref ref-type="bibr" rid="article-25150.r23">[23]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Calcitonin Gene-related Peptide Therapy</bold>
</p>
          </list-item>
        </list>
        <p>U.S. FDA approved Erenumab for the treatment of migraine prevention in May 2018. It is a monoclonal antibody that mediates the transmission of migraine pain by binding to the calcitonin gene-related peptide receptor. It&#x000a0;comes as&#x000a0;a monthly subcutaneous injection. Common side effects include injection site reaction, constipation, and cramps.<xref ref-type="bibr" rid="article-25150.r3">[3]</xref><xref ref-type="bibr" rid="article-25150.r25">[25]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Others</bold>
</p>
          </list-item>
        </list>
        <p>Some other medications that have some but little efficacy for migraine prevention include magnesium, vitamin B2, coenzyme Q10, and botulinum toxin.<xref ref-type="bibr" rid="article-25150.r26">[26]</xref><xref ref-type="bibr" rid="article-25150.r27">[27]</xref> The benefits of botulinum toxin A have not been statistically proven for treating an episodic migraine headache; however, it is proven effective for treating chronic headaches.</p>
        <p>Methysergide and phenelzine are used as last resort for severe and refractory cases. Use for more than six months can cause cardiac and retroperitoneal fibrosis.<xref ref-type="bibr" rid="article-25150.r27">[27]</xref><xref ref-type="bibr" rid="article-25150.r28">[28]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>
<bold>Alternative Therapies</bold>
</bold>
</p>
          </list-item>
        </list>
        <p>Butterbur and feverfew are&#x000a0;two herbal medications available for use for migraine prophylaxis. Studies have failed to prove any substantial benefit with feverfew. Butterbur extract made from underground parts of the plant has been endorsed by the American Academy of Neurology and the American Headache Society to reduce the frequency of migraines.<xref ref-type="bibr" rid="article-25150.r3">[3]</xref><xref ref-type="bibr" rid="article-25150.r27">[27]</xref>&#x000a0;Although the American Academy of Neurology&#x000a0;withdrew its 2012 recommendation on complementary therapy due to serious safety concerns around butterbur, the Canadian Headache Society continues to strongly recommend its use.<xref ref-type="bibr" rid="article-25150.r29">[29]</xref></p>
        <p>
<bold>
<bold>2. Non-pharmacological Therapies</bold>
</bold>
</p>
        <p>Identifying and modifying the trigger, if possible, is important. It is helpful to maintain headache diaries to identify triggers and follow responses when triggers become modified. Therapies that can help prevent migraines include relaxation, acupuncture, massage, cognitive behavior therapy, and biofeedback techniques.<xref ref-type="bibr" rid="article-25150.r3">[3]</xref><xref ref-type="bibr" rid="article-25150.r30">[30]</xref>&#x000a0;The FDA approved a transcutaneous electrical nerve stimulation (TENS) device in March 2014 for migraine prevention. More studies are needed to determine its long-term efficacy.<xref ref-type="bibr" rid="article-25150.r13">[13]</xref><xref ref-type="bibr" rid="article-25150.r30">[30]</xref></p>
        <p>
<bold>2012 AHS/AAN Guidelines for Migraine Prevention in Adults </bold>
</p>
        <p>
<bold>Medications are Divided&#x000a0;into Three Groups</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Level A&#x000a0;(medications that have proven effectiveness and should be offered to patients who require migraine prophylaxis): Sodium valproate, valproic acid,&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Level B&#x000a0;(medications that are probably effective and should be considered for migraine prevention): Amitriptyline, naproxen, fenoprofen, ketoprofen, ibuprofen, magnesium, atenolol, venlafaxine, riboflavin, histamine.</p>
          </list-item>
          <list-item>
            <p>Level C&#x000a0;(medications with possible effectiveness and may be considered for migraine prevention): Candesartan, carbamazepine, lisinopril, pindolol, nebivolol, clonidine, cyproheptadine, coenzyme Q10.<xref ref-type="bibr" rid="article-25150.r31">[31]</xref></p>
          </list-item>
        </list>
        <p>The following is a list of medications as per the current guidance for migraine prophylaxis:</p>
        <p>
<bold>First-line agents (established efficacy based on evidence):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Divalproex</p>
          </list-item>
          <list-item>
            <p>Propranolol</p>
          </list-item>
          <list-item>
            <p>Timolol</p>
          </list-item>
          <list-item>
            <p>Topiramate</p>
          </list-item>
          <list-item>
            <p>Frovatriptan</p>
          </list-item>
          <list-item>
            <p>Metoprolol</p>
          </list-item>
        </list>
        <p>
<bold>Second-line agents (probably established efficacy based on evidence):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Amitriptyline</p>
          </list-item>
          <list-item>
            <p>Atenolol</p>
          </list-item>
          <list-item>
            <p>Nadolol</p>
          </list-item>
          <list-item>
            <p>Naratriptan</p>
          </list-item>
          <list-item>
            <p>venlafaxine</p>
          </list-item>
          <list-item>
            <p>Zolmitriptan</p>
          </list-item>
        </list>
        <p>
<bold>Other medications (less evidence-based) for episodic migraine prevention:</bold>
</p>
        <p>
<bold>Possibly Effective</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Candesartan</p>
          </list-item>
          <list-item>
            <p>Carbamazepine</p>
          </list-item>
          <list-item>
            <p>Lisinopril</p>
          </list-item>
          <list-item>
            <p>Nebivolol</p>
          </list-item>
          <list-item>
            <p>Nicardipine</p>
          </list-item>
        </list>
        <p>
<bold>Conflicting or Inadequate Data to Support or Refute the Use</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bisoprolol</p>
          </list-item>
          <list-item>
            <p>Fluoxetine</p>
          </list-item>
          <list-item>
            <p>Gabapentin</p>
          </list-item>
          <list-item>
            <p>Nifedipine</p>
          </list-item>
          <list-item>
            <p>Nimodipine</p>
          </list-item>
          <list-item>
            <p>Pindolol</p>
          </list-item>
          <list-item>
            <p>Protriptyline</p>
          </list-item>
          <list-item>
            <p>Verapamil</p>
          </list-item>
        </list>
        <p>
<bold>Ineffective</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acebutolol</p>
          </list-item>
          <list-item>
            <p>Lamotrigine</p>
          </list-item>
          <list-item>
            <p>Oxcarbazepine</p>
          </list-item>
          <list-item>
            <p>Telmisartan</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25150.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Migraine Prophylaxis in Children</bold>
</p>
        <p>Propranolol is commonly prescribed for migraine preventive treatment in children, although studies have shown conflicting results. Similarly, topiramate is commonly prescribed for children, but its efficacy is questionable.</p>
        <p>Data is insufficient for other medications like cyproheptadine, amitriptyline, and&#x000a0;valproic acid. Flunarizine is believed to be effective&#x000a0;for&#x000a0;preventing migraines in children but is not available in the United States.<xref ref-type="bibr" rid="article-25150.r3">[3]</xref><xref ref-type="bibr" rid="article-25150.r1">[1]</xref><xref ref-type="bibr" rid="article-25150.r32">[32]</xref></p>
        <p>
<bold>Migraine Prophylaxis in Pregnancy</bold>
</p>
        <p>It is imperative to maintain a cautious approach. Risks and benefits should be discussed with the patient&#x000a0;in detail. Labetalol at a dose of 150 mg twice per day has shown some&#x000a0;benefit in pregnant women. Propranolol, topiramate, amitriptyline, fluoxetine, and gabapentin are pregnancy category C drugs. Valproic acid is teratogenic and contraindicated, and the use of lisinopril and candesartan is not recommended for pregnant women.<xref ref-type="bibr" rid="article-25150.r33">[33]</xref></p>
      </sec>
      <sec id="article-25150.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Recurrent migraines are often functionally disabling and can impair quality of life. Prophylactic therapy may decrease the frequency, severity, and duration of migraine attacks, increase responsiveness to acute migraine therapy and improve quality of life.&#x000a0;Migraines are&#x000a0;different from&#x000a0;other headaches by the following attributes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lasting 4 to 72 hours</p>
          </list-item>
          <list-item>
            <p>Unilateral location</p>
          </list-item>
          <list-item>
            <p>Pulsating quality</p>
          </list-item>
          <list-item>
            <p>Moderate to severe intensity</p>
          </list-item>
          <list-item>
            <p>Aggravated by physical activity</p>
          </list-item>
          <list-item>
            <p>Associations with nausea, vomiting, phonophobia, or photophobia</p>
          </list-item>
        </list>
        <p>Migraine headaches may have an aural phase before the onset of the headache.<xref ref-type="bibr" rid="article-25150.r34">[34]</xref> Chronic and episodic migraines fall in a spectrum of migraine disorders; however, they are distinct clinical entities.<xref ref-type="bibr" rid="article-25150.r35">[35]</xref>&#x000a0;Chronic migraine is uncommon (found in 1 to 5% of patients with migraine) and is defined as a headache lasting 15 times a month or more for at least three months.<xref ref-type="bibr" rid="article-25150.r34">[34]</xref>&#x000a0;Patients with chronic migraine have a poor quality of life.<xref ref-type="bibr" rid="article-25150.r35">[35]</xref>&#x000a0;Prophylaxis for episodic migraine may reduce headache severity and frequency and prevent progression to chronic migraine.</p>
      </sec>
      <sec id="article-25150.s6" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>Once the need for prophylaxis&#x000a0;is established, the following consensus-based principles of care should be adhered to improve the success of prophylactic treatment:</p>
        <list list-type="bullet">
          <list-item>
            <p>Start medications with the highest evidence-based effectiveness.</p>
          </list-item>
          <list-item>
            <p>Avoid agents that may exacerbate comorbid conditions.<xref ref-type="bibr" rid="article-25150.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Begin&#x000a0;with the lowest effective dose and increase every two to four weeks to achieve the therapeutic effect and stop if the patient develops adverse effects.</p>
          </list-item>
          <list-item>
            <p>Successful treatment is described as a 50% reduction in the episodes of headaches or days, a significant shortening of episode duration, or an increase in response to acute therapy.</p>
          </list-item>
          <list-item>
            <p>If headaches are under control for at least 6 to 12 months, therapy should be slowly tapered and discontinued.<xref ref-type="bibr" rid="article-25150.r4">[4]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25150.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Migraine management requires the efforts of an interprofessional healthcare team that includes clinicians, nurses, and pharmacists. When the clinician decides to implement migraine prophylaxis, the pharmacist should perform medication reconciliation and be available to recommend potential agents. The nurse can counsel the patient on administration and serve as a liaison between the prescriber and other healthcare team members. This interprofessional approach will yield optimal patient outcomes with the fewest adverse events. [Level 5]</p>
        <p>Around 18% of women and 6% of men in the United States suffer from migraine headaches, with an estimated total prevalence of around 16%. It is a common cause of emergency department and clinic visits and causes significant financial and health burdens. Less than 13% of migraine patients are believed to be on prophylactic therapy, whereas it is estimated that around&#x000a0;38% of episodic migraine patients would actually benefit from prophylactic therapy. It is important to educate all headache patients about identifying their headache type and frequency. Simple strategies like maintaining a headache diary to help identify the frequency, severity, and triggers of headaches can help identify patients needing prophylactic treatment.<xref ref-type="bibr" rid="article-25150.r2">[2]</xref><xref ref-type="bibr" rid="article-25150.r3">[3]</xref></p>
      </sec>
      <sec id="article-25150.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25150&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25150">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25150/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25150">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25150.s9">
        <title>References</title>
        <ref id="article-25150.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smitherman</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Loder</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies.</article-title>
            <source>Headache</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>53</volume>
            <issue>3</issue>
            <fpage>427</fpage>
            <page-range>427-36</page-range>
            <pub-id pub-id-type="pmid">23470015</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Bigal</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>WF</given-names>
              </name>
              <collab>AMPP Advisory Group</collab>
            </person-group>
            <article-title>Migraine prevalence, disease burden, and the need for preventive therapy.</article-title>
            <source>Neurology</source>
            <year>2007</year>
            <month>Jan</month>
            <day>30</day>
            <volume>68</volume>
            <issue>5</issue>
            <fpage>343</fpage>
            <page-range>343-9</page-range>
            <pub-id pub-id-type="pmid">17261680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Migraine Headache Prophylaxis.</article-title>
            <source>Am Fam Physician</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>99</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-24</page-range>
            <pub-id pub-id-type="pmid">30600979</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Preventive Migraine Treatment.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>21</volume>
            <issue>4 Headache</issue>
            <fpage>973</fpage>
            <page-range>973-89</page-range>
            <pub-id pub-id-type="pmid">26252585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parikh</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Preventive Treatment for Episodic Migraine.</article-title>
            <source>Neurol Clin</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>753</fpage>
            <page-range>753-770</page-range>
            <pub-id pub-id-type="pmid">31563231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finocchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sivori</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Food as trigger and aggravating factor of migraine.</article-title>
            <source>Neurol Sci</source>
            <year>2012</year>
            <month>May</month>
            <volume>33 Suppl 1</volume>
            <fpage>S77</fpage>
            <page-range>S77-80</page-range>
            <pub-id pub-id-type="pmid">22644176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peroutka</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>What turns on a migraine? A systematic review of migraine precipitating factors.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>10</issue>
            <fpage>454</fpage>
            <pub-id pub-id-type="pmid">25160711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Starling</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Best practices for patients with chronic migraine: burden, diagnosis, and management in primary care.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>90</volume>
            <issue>3</issue>
            <fpage>408</fpage>
            <page-range>408-14</page-range>
            <pub-id pub-id-type="pmid">25744118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Noseda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burstein</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain.</article-title>
            <source>Pain</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>154 Suppl 1</volume>
            <pub-id pub-id-type="pmid">24347803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spierings</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of migraine and action of antimigraine medications.</article-title>
            <source>Med Clin North Am</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>85</volume>
            <issue>4</issue>
            <fpage>943</fpage>
            <page-range>943-58, vi-vii</page-range>
            <pub-id pub-id-type="pmid">11480266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Modi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lowder</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Medications for migraine prophylaxis.</article-title>
            <source>Am Fam Physician</source>
            <year>2006</year>
            <month>Jan</month>
            <day>01</day>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-8</page-range>
            <pub-id pub-id-type="pmid">16417067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cogbill</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Santana-Davila</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eldredge</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Gradall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sehgal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuester</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>e0130733</fpage>
            <pub-id pub-id-type="pmid">26172390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Argoff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>E</given-names>
              </name>
              <collab>Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society</collab>
            </person-group>
            <article-title>Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Apr</month>
            <day>24</day>
            <volume>78</volume>
            <issue>17</issue>
            <fpage>1337</fpage>
            <page-range>1337-45</page-range>
            <pub-id pub-id-type="pmid">22529202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freitag</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Winner</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Deaton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sommerville</surname>
                <given-names>K</given-names>
              </name>
              <collab>Depakote ER Migraine Study Group</collab>
            </person-group>
            <article-title>A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis.</article-title>
            <source>Neurology</source>
            <year>2002</year>
            <month>Jun</month>
            <day>11</day>
            <volume>58</volume>
            <issue>11</issue>
            <fpage>1652</fpage>
            <page-range>1652-9</page-range>
            <pub-id pub-id-type="pmid">12058094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Saper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rupnow</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Biondi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hulihan</surname>
                <given-names>J</given-names>
              </name>
              <collab>CAPSS-277 Investigator Group</collab>
            </person-group>
            <article-title>Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.</article-title>
            <source>Clin Ther</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>542</fpage>
            <page-range>542-59</page-range>
            <pub-id pub-id-type="pmid">19393844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mulleners</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Chronicle</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>McCrory</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2013</year>
            <month>Jun</month>
            <day>24</day>
            <volume>2013</volume>
            <issue>6</issue>
            <fpage>CD010611</fpage>
            <pub-id pub-id-type="pmid">23797677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mulleners</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Chronicle</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>McCrory</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Topiramate for the prophylaxis of episodic migraine in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2013</year>
            <month>Jun</month>
            <day>24</day>
            <volume>2013</volume>
            <issue>6</issue>
            <fpage>CD010610</fpage>
            <pub-id pub-id-type="pmid">23797676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Linde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mulleners</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Chronicle</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>McCrory</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2013</year>
            <month>Jun</month>
            <day>24</day>
            <volume>2013</volume>
            <issue>6</issue>
            <fpage>CD010609</fpage>
            <pub-id pub-id-type="pmid">23797675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>MX</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>YD</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressants for preventing migraine in adults.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>96</volume>
            <issue>22</issue>
            <fpage>e6989</fpage>
            <pub-id pub-id-type="pmid">28562550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bulut</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berilgen</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Baran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tekatas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Atmaca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mungen</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>107</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-8</page-range>
            <pub-id pub-id-type="pmid">15567552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schrader</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stovner</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Helde</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sand</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bovim</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study.</article-title>
            <source>BMJ</source>
            <year>2001</year>
            <month>Jan</month>
            <day>06</day>
            <volume>322</volume>
            <issue>7277</issue>
            <fpage>19</fpage>
            <page-range>19-22</page-range>
            <pub-id pub-id-type="pmid">11141144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tronvik</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stovner</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Helde</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sand</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bovim</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.</article-title>
            <source>JAMA</source>
            <year>2003</year>
            <month>Jan</month>
            <day>01</day>
            <volume>289</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-9</page-range>
            <pub-id pub-id-type="pmid">12503978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>14</issue>
            <fpage>2063</fpage>
            <page-range>2063-70</page-range>
            <pub-id pub-id-type="pmid">25100506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maasumi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kriegler</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Menstrual Migraine and Treatment Options: Review.</article-title>
            <source>Headache</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>57</volume>
            <issue>2</issue>
            <fpage>194</fpage>
            <page-range>194-208</page-range>
            <pub-id pub-id-type="pmid">27910087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goadsby</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hallstr&#x000f6;m</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Broessner</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonner</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sapra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Picard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mikol</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Lenz</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>A Controlled Trial of Erenumab for Episodic Migraine.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Nov</month>
            <day>30</day>
            <volume>377</volume>
            <issue>22</issue>
            <fpage>2123</fpage>
            <page-range>2123-2132</page-range>
            <pub-id pub-id-type="pmid">29171821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Luckner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riederer</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Magnesium in Migraine Prophylaxis-Is There an Evidence-Based Rationale? A Systematic Review.</article-title>
            <source>Headache</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-209</page-range>
            <pub-id pub-id-type="pmid">29131326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajapakse</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Nutraceuticals in Migraine: A Summary of Existing Guidelines for Use.</article-title>
            <source>Headache</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>808</fpage>
            <page-range>808-16</page-range>
            <pub-id pub-id-type="pmid">26954394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simpson</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hallett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Comella</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Potrebic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jankovic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karp</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Naumann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>So</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Yablon</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>May</month>
            <day>10</day>
            <volume>86</volume>
            <issue>19</issue>
            <fpage>1818</fpage>
            <page-range>1818-26</page-range>
            <pub-id pub-id-type="pmid">27164716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Freitag</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dodick</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Argoff</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>E</given-names>
              </name>
              <collab>Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society</collab>
            </person-group>
            <article-title>Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.</article-title>
            <source>Neurology</source>
            <year>2012</year>
            <month>Apr</month>
            <day>24</day>
            <volume>78</volume>
            <issue>17</issue>
            <fpage>1346</fpage>
            <page-range>1346-53</page-range>
            <pub-id pub-id-type="pmid">22529203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwedt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Neurostimulation for Treatment of Migraine and Cluster Headache.</article-title>
            <source>Pain Med</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>1827</fpage>
            <page-range>1827-34</page-range>
            <pub-id pub-id-type="pmid">26177612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loder</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Burch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rizzoli</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines.</article-title>
            <source>Headache</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>52</volume>
            <issue>6</issue>
            <fpage>930</fpage>
            <page-range>930-45</page-range>
            <pub-id pub-id-type="pmid">22671714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ashwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hershey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hirtz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yonker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silberstein</surname>
                <given-names>S</given-names>
              </name>
              <collab>American Academy of Neurology Quality Standards Subcommittee</collab>
              <collab>Practice Committee of the Child Neurology Society</collab>
            </person-group>
            <article-title>Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.</article-title>
            <source>Neurology</source>
            <year>2004</year>
            <month>Dec</month>
            <day>28</day>
            <volume>63</volume>
            <issue>12</issue>
            <fpage>2215</fpage>
            <page-range>2215-24</page-range>
            <pub-id pub-id-type="pmid">15623677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silberstein</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Headaches in pregnancy.</article-title>
            <source>J Headache Pain</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>172</fpage>
            <page-range>172-4</page-range>
            <pub-id pub-id-type="pmid">16362655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <article-title>Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</article-title>
            <source>Cephalalgia</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-211</page-range>
            <pub-id pub-id-type="pmid">29368949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25150.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katsarava</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Manack</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Lipton</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Defining the differences between episodic migraine and chronic migraine.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-92</page-range>
            <pub-id pub-id-type="pmid">22083262</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
